Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688336 · ClinicalTrials.gov registry record · Phase 2
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01688336 is a Phase 2 study that was terminated before completion, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 9 participants.
The verdict
NCT01688336, a Phase 2 study, was terminated before completion, sponsored by UNC Lineberger Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic cancer.
Interventions
- DRUG FOLFIRINOX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01688336
The ClinicalTrials.gov registry entry for NCT01688336 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FOLFIRINOX is the first listed.
NCT01688336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01688336 about?
NCT01688336 is a clinical study titled "FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer". This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic cancer.
What is the current status of trial NCT01688336?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2012-01. Estimated completion is 2016-11-22.
What interventions are being tested in trial NCT01688336?
The interventions under investigation include: FOLFIRINOX (DRUG).
Who is sponsoring clinical trial NCT01688336?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.